James J Nawarskas

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi request reprint HMG-CoA reductase inhibitors and coenzyme Q10
    James J Nawarskas
    Department of Pharmacy, University of New Mexico, College of Pharmacy, Albuquerque, New Mexico 87131 0001, USA
    Cardiol Rev 13:76-9. 2005
  2. ncbi request reprint Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan
    J J Nawarskas
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania, USA
    Am J Hypertens 12:784-9. 1999
  3. ncbi request reprint Omapatrilat: a unique new agent for the treatment of cardiovascular disease
    J J Nawarskas
    University of New Mexico College of Pharmacy, 2502 Marble Northeast, Albuquerque, NM 87131 5691, USA
    Heart Dis 2:266-74. 2000
  4. ncbi request reprint Bivalirudin: a new approach to anticoagulation
    J J Nawarskas
    College of Pharmacy, University of New Mexico, Albuquerque 87131 5691, USA
    Heart Dis 3:131-7. 2001
  5. ncbi request reprint Levosimendan: a unique approach to the treatment of heart failure
    James J Nawarskas
    University of New Mexico, College of Pharmacy, Albuquerque, New Mexico 87131 5691, USA
    Heart Dis 4:265-71. 2002
  6. ncbi request reprint Clopidogrel--statin interaction
    James J Nawarskas
    University of New Mexico, College of Pharmacy, Albuquerque, NM, USA
    Cardiol Rev 12:236-9. 2004
  7. ncbi request reprint Treatment options for patients with poor clopidogrel response
    Daniela I Roberts
    From the New Mexico VA Health Care System and University of New Mexico College of Pharmacy, Albuquerque, NM
    Cardiol Rev 21:309-17. 2013
  8. pmc Blood pressure monitoring technique impacts hypertension treatment
    Gretchen M Ray
    University of New Mexico College of Pharmacy, MSC 09 5360, Albuquerque, NM 87131, USA
    J Gen Intern Med 27:623-9. 2012
  9. ncbi request reprint The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents
    Kathryn J A Gruchalla
    University of New Mexico, College of Pharmacy, Albuquerque, New Mexico 87131 0001, USA
    Cardiol Rev 14:88-98. 2006
  10. ncbi request reprint The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions
    Gretchen M Ray
    University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87131 0001, USA
    Cardiol Rev 14:143-50. 2006

Collaborators

Detail Information

Publications18

  1. ncbi request reprint HMG-CoA reductase inhibitors and coenzyme Q10
    James J Nawarskas
    Department of Pharmacy, University of New Mexico, College of Pharmacy, Albuquerque, New Mexico 87131 0001, USA
    Cardiol Rev 13:76-9. 2005
    ....
  2. ncbi request reprint Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan
    J J Nawarskas
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania, USA
    Am J Hypertens 12:784-9. 1999
    ..Concentrations of TXB2 were suppressed to <10% in both groups with ASA. This study demonstrates that 81 to 325 mg/day ASA exerts no significant effect on BP in essential hypertensives taking enalapril or losartan...
  3. ncbi request reprint Omapatrilat: a unique new agent for the treatment of cardiovascular disease
    J J Nawarskas
    University of New Mexico College of Pharmacy, 2502 Marble Northeast, Albuquerque, NM 87131 5691, USA
    Heart Dis 2:266-74. 2000
    ....
  4. ncbi request reprint Bivalirudin: a new approach to anticoagulation
    J J Nawarskas
    College of Pharmacy, University of New Mexico, Albuquerque 87131 5691, USA
    Heart Dis 3:131-7. 2001
    ..Larger-scale studies are indicated and are currently being performed, the results of which will more definitively define the role of bivalirudin for the treatment of cardiovascular disease...
  5. ncbi request reprint Levosimendan: a unique approach to the treatment of heart failure
    James J Nawarskas
    University of New Mexico, College of Pharmacy, Albuquerque, New Mexico 87131 5691, USA
    Heart Dis 4:265-71. 2002
    ..No clinically significant drug-drug interactions have been reported with levosimendan to date. The clinical future of levosimendan will depend on the results of larger, ongoing clinical trials...
  6. ncbi request reprint Clopidogrel--statin interaction
    James J Nawarskas
    University of New Mexico, College of Pharmacy, Albuquerque, NM, USA
    Cardiol Rev 12:236-9. 2004
    ..Until then, the weight of the evidence does not currently support a change in prescribing patterns for the sole purpose of avoiding a potential statin-clopidogrel interaction...
  7. ncbi request reprint Treatment options for patients with poor clopidogrel response
    Daniela I Roberts
    From the New Mexico VA Health Care System and University of New Mexico College of Pharmacy, Albuquerque, NM
    Cardiol Rev 21:309-17. 2013
    ..Much research is needed and is currently underway in this area, which will be helpful in establishing future treatment protocols for patients with poor clopidogrel response. ..
  8. pmc Blood pressure monitoring technique impacts hypertension treatment
    Gretchen M Ray
    University of New Mexico College of Pharmacy, MSC 09 5360, Albuquerque, NM 87131, USA
    J Gen Intern Med 27:623-9. 2012
    ..In 2005 the American Heart Association (AHA) released updated recommendations for blood pressure (BP) monitoring in order to ensure accurate BP measurements...
  9. ncbi request reprint The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents
    Kathryn J A Gruchalla
    University of New Mexico, College of Pharmacy, Albuquerque, New Mexico 87131 0001, USA
    Cardiol Rev 14:88-98. 2006
    ....
  10. ncbi request reprint The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions
    Gretchen M Ray
    University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87131 0001, USA
    Cardiol Rev 14:143-50. 2006
    ....
  11. ncbi request reprint Ximelagatran: a new oral anticoagulant
    Lenka Hrebickova
    University of New Mexico College of Pharmacy, Albuquerque, NM 87131, USA
    Heart Dis 5:397-408. 2003
    ..The results of these trials are eagerly awaited in helping to defining the place in therapy for this promising new agent...
  12. doi request reprint Ticagrelor: a novel reversible oral antiplatelet agent
    James J Nawarskas
    University of New Mexico College of Pharmacy, Albuquerque, NM 87131 0001, USA
    Cardiol Rev 19:95-100. 2011
    ..Nonetheless, ticagrelor is a drug that has the potential to change the standard of care of patients with acute coronary syndromes...
  13. doi request reprint Pharmacotherapeutic management of pulmonary arterial hypertension
    Joe R Anderson
    University of New Mexico College of Pharmacy, Albuquerque, NM 87131 0001, USA
    Cardiol Rev 18:148-62. 2010
    ..The purpose of this drug highlight is to provide the reader with an update of the pharmacotherapeutic treatment of PAH...
  14. doi request reprint Hydrochlorothiazide versus chlorthalidone in the management of hypertension
    Kimberly M Neff
    New Mexico VA Health Care System, Albuquerque, NM, USA
    Cardiol Rev 18:51-6. 2010
    ..A head-to-head study looking at hard clinical outcomes, which may or may not ever be performed, may be the only way to resolve the ongoing debate as to which is the preferred thiazide for treating hypertension...
  15. doi request reprint Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women
    Ludmila N Bakhireva
    College of Pharmacy, University of New Mexico, Albuquerque, New Mexico Department of Family and Community Medicine, School of Medicine, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Pharmacotherapy 30:879-87. 2010
    ..To examine the role of concurrent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use and postmenopausal hormone therapy on osteoporosis-related fractures...
  16. ncbi request reprint Ranolazine. A metabolic modulator for the treatment of chronic stable angina
    Joe R Anderson
    University of New Mexico College of Pharmacy, Albuquerque, NM 87131 0001, USA
    Cardiol Rev 13:202-10. 2005
    ..Ongoing clinical trials will help further establish the role of ranolazine in the treatment of cardiovascular disorders...
  17. ncbi request reprint Paclitaxel-eluting stents in coronary artery disease
    James J Nawarskas
    College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Am J Health Syst Pharm 62:2241-51. 2005
    ..Clinical information regarding paclitaxel-eluting coronary artery stents is reviewed...
  18. ncbi request reprint Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure
    Tera D Moore
    South Texas Veterans Health Care System, San Antonio, TX, USA
    Heart Dis 5:354-63. 2003
    ..Its exact place in therapy will in large part be determined by its cost and whether or not future studies will be able to demonstrate a clinical benefit of this agent over spironolactone or other currently available treatments...